British Journal of Urology · 2011 · 17 citations · 24 references
MedicineOncologySurgeryOncologic SurgerySurgical OncologyVascular SurgeryKidney CancerKidney SurgeryRenal Cell CarcinomaRenal SurgeryClavien-dindo ClassificationKidney Cancer SurgeryKidney Tumor SurgeryOverall MortalityPerioperative Mortality PredictionRenal Cell Carcinoma SurgeryRenal Tumor SurgerySurgical Nephrectomy
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Patients should undergo surgery, although in the recent past some case series reported thrombus shrinkage with target therapies. Operations can be performed safely. The study adds the use of a standardized classification system for perioperative complications and reports less positive results with neoadjuvant target therapies. OBJECTIVE • To present a single‐centre experience of surgery for kidney cancer involving vena cava thrombus with surgical technique, complications and outcome using a standardized classification system for perioperative complications. PATIENTS AND METHODS • Sixty‐eight consecutive cases were retrospectively analysed. Thrombus extension was at level I (but inside the vena cava) in 10 cases, level II in 28 cases, level III in 18 cases and level IV in 12 cases; 18 patients had distant metastases. • Radical tumour nephrectomy was performed in all cases. Complete liver mobilization was carried out in 23 cases and cardiovascular bypass with circulatory arrest was performed in five cases. • Follow‐up was available for 66 patients. Median follow‐up was 29 months (interquartile range 30.75). RESULTS • The 28‐day mortality was 0%. • According to the Clavien–Dindo classification there were two grade 1, 54 grade 2, two grade 3a, two grade 3b and two grade 4a perioperative complications. • The factors pN, grading and metastases at presentation predicted overall survival in univariate analyses. In a multivariate model none of the factors age, metastases at presentation, pN, WHO‐grading, American Society of Anesthesiologists score, tumour size and thrombus level significantly predicted survival. • Immediate target therapy with neoadjuvant intention in three patients did not result in surgical therapy. CONCLUSIONS • Aggressive surgical treatment causes no perioperative mortality and leads to a low rate of grade 3 and grade 4 complications (8.8%). • A median overall survival of 47 months shows that surgical treatment has favourable results in these patients.
24
The Clavien-Dindo Classification of Surgical Complications
Pierre A. Clavien, Jeffrey Barkun, Michelle Oliveira et al. · Annals of Surgery · 2009 · 11.3K citations
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text
Medicine, Nephrology, Oncology +11
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations
Medicine, Oncology, Chemotherapy +10